Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases
- PMID: 22463590
- DOI: 10.2174/156800912801784839
Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases
Abstract
Aurora kinases and cyclin-dependent kinases, which play critical roles in the cell cycle and are frequently overexpressed in a variety of tumors, have been suggested as attractive targets for cancer therapy. JNJ-7706621, a recently identified dual inhibitor of these kinases, is reported to induce cell cycle arrest, endoreduplication, and apoptosis. In the present study, we further investigated the molecular mechanisms underlying these effects. The inhibitor arrested various cells at G2 phase at low concentration, and at both G1 and G2 phases at high concentration. JNJ-7706621 did not prevent localization of Aurora A to the spindle poles, but did inhibit other centrosomal proteins such as TOG, Nek2, and TACC3 in early mitotic phase. Similarly, the drug did not prevent localization of Aurora B to the kinetochore, but did inhibit other chromosomal passenger proteins such as Survivin and INCENP. In the cells exposed to JNJ-7706621 after nocodazole release, Aurora B, INCENP, and Survivin became relocated to the peripheral region of chromosomes, but Plk1 and Prc1 were localized on microtubules in later mitotic phase. Treatment of nocodazole-synchronized cells with JNJ-7706621 was able to override mitotic arrest by preventing spindle checkpoint signaling, resulting in failure of chromosome alignment and segregation. Injection of the drug significantly inhibited the growth of TC135 Ewing's sarcoma cells transplanted into athymic mice by cell cycle arrest and apoptosis. JNJ-7706621 is a unique inhibitor regulating cell cycle progression at multiple points, suggesting that it could be useful for cell cycle analysis and therapy of various cancers, including Ewing's sarcoma.
Similar articles
-
The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases.Cancer Res. 2005 Oct 1;65(19):9038-46. doi: 10.1158/0008-5472.CAN-05-0882. Cancer Res. 2005. PMID: 16204078
-
Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.Cell Cycle. 2009 Jun 15;8(12):1921-9. doi: 10.4161/cc.8.12.8741. Epub 2009 Jun 15. Cell Cycle. 2009. PMID: 19440047
-
Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells.Mol Cancer Ther. 2009 Jul;8(7):2046-56. doi: 10.1158/1535-7163.MCT-09-0323. Epub 2009 Jul 7. Mol Cancer Ther. 2009. PMID: 19584233
-
Aurora-B kinase inhibitors for cancer chemotherapy.Mini Rev Med Chem. 2008 Dec;8(14):1514-25. doi: 10.2174/138955708786786480. Mini Rev Med Chem. 2008. PMID: 19075809 Review.
-
Emerging cancer therapeutic opportunities by inhibiting mitotic kinases.Curr Opin Pharmacol. 2008 Aug;8(4):375-83. doi: 10.1016/j.coph.2008.06.013. Epub 2008 Jul 30. Curr Opin Pharmacol. 2008. PMID: 18644252 Review.
Cited by
-
CDK inhibitors in cancer therapy, an overview of recent development.Am J Cancer Res. 2021 May 15;11(5):1913-1935. eCollection 2021. Am J Cancer Res. 2021. PMID: 34094661 Free PMC article. Review.
-
G2/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: the old, the new, and the future.Cancer Biol Med. 2018 Nov;15(4):354-374. doi: 10.20892/j.issn.2095-3941.2018.0030. Cancer Biol Med. 2018. PMID: 30766748 Free PMC article.
-
The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines.Front Oncol. 2019 Nov 29;9:1301. doi: 10.3389/fonc.2019.01301. eCollection 2019. Front Oncol. 2019. PMID: 31850205 Free PMC article.
-
Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer.BMC Urol. 2015 Aug 29;15:90. doi: 10.1186/s12894-015-0085-7. BMC Urol. 2015. PMID: 26320076 Free PMC article.
-
A new method for network bioinformatics identifies novel drug targets for mucinous ovarian carcinoma.NAR Genom Bioinform. 2024 Aug 24;6(3):lqae096. doi: 10.1093/nargab/lqae096. eCollection 2024 Sep. NAR Genom Bioinform. 2024. PMID: 39184376 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous